Research progress in adjuvant therapy after concurrent chemoradiotherapy for locally advanced cervical cancer
10.3760/cma.j.cn113030-20231016-00133
- VernacularTitle:局部晚期宫颈癌同步放化疗后辅助治疗研究进展
- Author:
Tian CHENG
1
;
Xianshu GAO
;
Xiaomei LI
;
Jiayan CHEN
Author Information
1. 北京大学第一医院放射治疗科，北京100034
- Keywords:
Uterine cervical neoplasms, locally advanced;
Concurrent chemoradiotherapy;
Adjuvant therapy;
Review
- From:
Chinese Journal of Radiation Oncology
2024;33(7):668-672
- CountryChina
- Language:Chinese
-
Abstract:
Cervical cancer is a malignant tumor of the female reproductive system, which is closely related to persistent infection with high-risk human papillomavirus (HPV). Locally advanced cervical cancer (LACC) refers to cervical cancer of stage IB3 to IVA [International Federation of Gynecology and Obstetrics (FIGO) 2018 staging], characterized by tumor diameter greater than 4 cm or invasion of adjacent tissues. The standard treatment for LACC is concurrent chemoradiotherapy, with cisplatin as the preferred chemotherapeutic agent. However, there is still a clinical need for further improvement of the overall prognosis of LACC, and exploring effective adjuvant treatment strategies after concurrent chemoradiotherapy to increase the cure rate and quality of life of LACC patients is an important topic in clinical practice. This article reviews the types, indications, effects and existing problems of adjuvant treatment after concurrent chemoradiotherapy for LACC.
